Bio Alliances

Dynavax GmbH/ Dynavax Europe (formerly known as MiGenTra Egypt Biotech) is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, Dynavax Europe has been dedicated to the development and manufacturing of vaccines and biopharmaceuticals. Dynavax Europe uses a state-of-the-art technology based on Hansenula polymorpha. The Hansenula polymorpha technology is a basis for a number of global vaccines and biopharmaceuticals registered in over 90 countries world-wide and distributed over national and supra-national organizations (UNICEF, PAHO etc.).

ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider with focus on cell line engineering, process development (upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Having almost 20 years of experience in mammalian cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain, including regulatory support for IND-filing. All of ProBioGEN services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ARTES Biotechnology is a globally working, well established and reliable technology provider for recombinant protein production. ARTES develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.

The Company's focus is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. Proteo is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases.

VALIDOGEN, formerly known as VTU Technology, is a leading Austrian contract research and development company. VALIDOGEN offers UNLOCK PICHIA - the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins. Founded in 2008, the company emerged to a globally recognized player in the field of Pichia pastoris based protein expression.